Efficacy and safety of tenofovir-based rescue therapy for chronic hepatitis B patients with previous nucleo(s/t)ide treatment failure

Cho I. Lee, So Young Kwon, Jeong Han Kim, Won Hyeok Choe, Chang Hong Lee, Eileen L. Yoon, Jong Eun Yeon, Kwan Soo Byun, Yun Soo Kim, Ju Hyun Kim

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

Background/Aims: We investigated the efficacy and safety of tenofovir disoproxil fumarate (TDF)-based treatment in chronic hepatitis B (CHB) patients who failed previous antiviral therapies. Methods: Seventeen patients who failed to achieve virological responses during sequential antiviral treatments were included. The patients were treated with TDF monotherapy (four patients) or a combination of TDF and lamivudine (13 patients) for a median of 42 months. Hepatitis B virus (HBV) DNA and hepatitis B e antigen (HBeAg) were measured, and renal function was also monitored. Results: Prior to TDF therapy, 180 M, 204 I/V/S, 181 T/V, 236 T, and 184 L mutations were detected. After TDF therapy, the median HBV DNA level decreased from 4.6 log10 IU/mL to 2.0 log10 IU/mL and to 1.6 log10 IU/mL at 12 and 24 months, respectively. HBV DNA became undetectable (?20 IU/mL) in 14.3%, 41.7%, and 100% of patients after 12, 24, and 48 months of treatment, respectively. HBeAg loss was observed in two patients. Viral breakthrough occurred in five patients who had skipped their medication. No significant changes in renal function were observed. Conclusions: TDF-based rescue treatment is effective in reducing HBV DNA levels and is safe for patients with CHB who failed prior antiviral treatments. Patients' adherence to medication is related to viral rebound.

Original languageEnglish
Pages (from-to)64-69
Number of pages6
JournalGut and Liver
Volume8
Issue number1
DOIs
Publication statusPublished - 2014 Jan 1

Fingerprint

Tenofovir
Chronic Hepatitis B
Treatment Failure
Safety
Hepatitis B virus
Antiviral Agents
Hepatitis B e Antigens
Therapeutics
DNA
Kidney
Lamivudine

Keywords

  • Antiviral agents
  • Hepatitis B
  • Resistance
  • Tenofovir
  • Treatment outcome

ASJC Scopus subject areas

  • Gastroenterology
  • Hepatology

Cite this

Efficacy and safety of tenofovir-based rescue therapy for chronic hepatitis B patients with previous nucleo(s/t)ide treatment failure. / Lee, Cho I.; Kwon, So Young; Kim, Jeong Han; Choe, Won Hyeok; Lee, Chang Hong; Yoon, Eileen L.; Yeon, Jong Eun; Byun, Kwan Soo; Kim, Yun Soo; Kim, Ju Hyun.

In: Gut and Liver, Vol. 8, No. 1, 01.01.2014, p. 64-69.

Research output: Contribution to journalArticle

Lee, Cho I. ; Kwon, So Young ; Kim, Jeong Han ; Choe, Won Hyeok ; Lee, Chang Hong ; Yoon, Eileen L. ; Yeon, Jong Eun ; Byun, Kwan Soo ; Kim, Yun Soo ; Kim, Ju Hyun. / Efficacy and safety of tenofovir-based rescue therapy for chronic hepatitis B patients with previous nucleo(s/t)ide treatment failure. In: Gut and Liver. 2014 ; Vol. 8, No. 1. pp. 64-69.
@article{2d5251914f474779a9fc81ce421ea625,
title = "Efficacy and safety of tenofovir-based rescue therapy for chronic hepatitis B patients with previous nucleo(s/t)ide treatment failure",
abstract = "Background/Aims: We investigated the efficacy and safety of tenofovir disoproxil fumarate (TDF)-based treatment in chronic hepatitis B (CHB) patients who failed previous antiviral therapies. Methods: Seventeen patients who failed to achieve virological responses during sequential antiviral treatments were included. The patients were treated with TDF monotherapy (four patients) or a combination of TDF and lamivudine (13 patients) for a median of 42 months. Hepatitis B virus (HBV) DNA and hepatitis B e antigen (HBeAg) were measured, and renal function was also monitored. Results: Prior to TDF therapy, 180 M, 204 I/V/S, 181 T/V, 236 T, and 184 L mutations were detected. After TDF therapy, the median HBV DNA level decreased from 4.6 log10 IU/mL to 2.0 log10 IU/mL and to 1.6 log10 IU/mL at 12 and 24 months, respectively. HBV DNA became undetectable (?20 IU/mL) in 14.3{\%}, 41.7{\%}, and 100{\%} of patients after 12, 24, and 48 months of treatment, respectively. HBeAg loss was observed in two patients. Viral breakthrough occurred in five patients who had skipped their medication. No significant changes in renal function were observed. Conclusions: TDF-based rescue treatment is effective in reducing HBV DNA levels and is safe for patients with CHB who failed prior antiviral treatments. Patients' adherence to medication is related to viral rebound.",
keywords = "Antiviral agents, Hepatitis B, Resistance, Tenofovir, Treatment outcome",
author = "Lee, {Cho I.} and Kwon, {So Young} and Kim, {Jeong Han} and Choe, {Won Hyeok} and Lee, {Chang Hong} and Yoon, {Eileen L.} and Yeon, {Jong Eun} and Byun, {Kwan Soo} and Kim, {Yun Soo} and Kim, {Ju Hyun}",
year = "2014",
month = "1",
day = "1",
doi = "10.5009/gnl.2014.8.1.64",
language = "English",
volume = "8",
pages = "64--69",
journal = "Gut and Liver",
issn = "1976-2283",
publisher = "Joe Bok Chung",
number = "1",

}

TY - JOUR

T1 - Efficacy and safety of tenofovir-based rescue therapy for chronic hepatitis B patients with previous nucleo(s/t)ide treatment failure

AU - Lee, Cho I.

AU - Kwon, So Young

AU - Kim, Jeong Han

AU - Choe, Won Hyeok

AU - Lee, Chang Hong

AU - Yoon, Eileen L.

AU - Yeon, Jong Eun

AU - Byun, Kwan Soo

AU - Kim, Yun Soo

AU - Kim, Ju Hyun

PY - 2014/1/1

Y1 - 2014/1/1

N2 - Background/Aims: We investigated the efficacy and safety of tenofovir disoproxil fumarate (TDF)-based treatment in chronic hepatitis B (CHB) patients who failed previous antiviral therapies. Methods: Seventeen patients who failed to achieve virological responses during sequential antiviral treatments were included. The patients were treated with TDF monotherapy (four patients) or a combination of TDF and lamivudine (13 patients) for a median of 42 months. Hepatitis B virus (HBV) DNA and hepatitis B e antigen (HBeAg) were measured, and renal function was also monitored. Results: Prior to TDF therapy, 180 M, 204 I/V/S, 181 T/V, 236 T, and 184 L mutations were detected. After TDF therapy, the median HBV DNA level decreased from 4.6 log10 IU/mL to 2.0 log10 IU/mL and to 1.6 log10 IU/mL at 12 and 24 months, respectively. HBV DNA became undetectable (?20 IU/mL) in 14.3%, 41.7%, and 100% of patients after 12, 24, and 48 months of treatment, respectively. HBeAg loss was observed in two patients. Viral breakthrough occurred in five patients who had skipped their medication. No significant changes in renal function were observed. Conclusions: TDF-based rescue treatment is effective in reducing HBV DNA levels and is safe for patients with CHB who failed prior antiviral treatments. Patients' adherence to medication is related to viral rebound.

AB - Background/Aims: We investigated the efficacy and safety of tenofovir disoproxil fumarate (TDF)-based treatment in chronic hepatitis B (CHB) patients who failed previous antiviral therapies. Methods: Seventeen patients who failed to achieve virological responses during sequential antiviral treatments were included. The patients were treated with TDF monotherapy (four patients) or a combination of TDF and lamivudine (13 patients) for a median of 42 months. Hepatitis B virus (HBV) DNA and hepatitis B e antigen (HBeAg) were measured, and renal function was also monitored. Results: Prior to TDF therapy, 180 M, 204 I/V/S, 181 T/V, 236 T, and 184 L mutations were detected. After TDF therapy, the median HBV DNA level decreased from 4.6 log10 IU/mL to 2.0 log10 IU/mL and to 1.6 log10 IU/mL at 12 and 24 months, respectively. HBV DNA became undetectable (?20 IU/mL) in 14.3%, 41.7%, and 100% of patients after 12, 24, and 48 months of treatment, respectively. HBeAg loss was observed in two patients. Viral breakthrough occurred in five patients who had skipped their medication. No significant changes in renal function were observed. Conclusions: TDF-based rescue treatment is effective in reducing HBV DNA levels and is safe for patients with CHB who failed prior antiviral treatments. Patients' adherence to medication is related to viral rebound.

KW - Antiviral agents

KW - Hepatitis B

KW - Resistance

KW - Tenofovir

KW - Treatment outcome

UR - http://www.scopus.com/inward/record.url?scp=84893126853&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84893126853&partnerID=8YFLogxK

U2 - 10.5009/gnl.2014.8.1.64

DO - 10.5009/gnl.2014.8.1.64

M3 - Article

VL - 8

SP - 64

EP - 69

JO - Gut and Liver

JF - Gut and Liver

SN - 1976-2283

IS - 1

ER -